152 related articles for article (PubMed ID: 38307409)
21. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
22. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
23. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
24. Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration.
Knab LM; Ebine K; Chow CR; Raza SS; Sahai V; Patel AP; Kumar K; Bentrem DJ; Grippo PJ; Munshi HG
Mol Cancer Res; 2014 Oct; 12(10):1440-8. PubMed ID: 24944064
[TBL] [Abstract][Full Text] [Related]
25. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
26. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
27. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
[TBL] [Abstract][Full Text] [Related]
28. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.
Salaymeh Y; Farago M; Sebban S; Shalom B; Pikarsky E; Katzav S
Life Sci Alliance; 2020 May; 3(5):. PubMed ID: 32277014
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
30. Loss of Heterozygosity for
Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
[TBL] [Abstract][Full Text] [Related]
31. Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer.
Azizi N; Toma J; Martin M; Khalid MF; Mousavi F; Win PW; Borrello MT; Steele N; Shi J; di Magliano MP; Pin CL
Oncogene; 2021 Apr; 40(17):3118-3135. PubMed ID: 33864001
[TBL] [Abstract][Full Text] [Related]
32. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
[TBL] [Abstract][Full Text] [Related]
33. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
Guo S; Shi X; Shen J; Gao S; Wang H; Shen S; Pan Y; Li B; Xu X; Shao Z; Jin G
Br J Cancer; 2020 Mar; 122(6):857-867. PubMed ID: 31969677
[TBL] [Abstract][Full Text] [Related]
34. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
35. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
36. Differential Cell Susceptibilities to Kras
Shi C; Pan FC; Kim JN; Washington MK; Padmanabhan C; Meyer CT; Kopp JL; Sander M; Gannon M; Beauchamp RD; Wright CV; Means AL
Cell Mol Gastroenterol Hepatol; 2019; 8(4):579-594. PubMed ID: 31310834
[TBL] [Abstract][Full Text] [Related]
37. Pdx1 expression in hematopoietic cells activates
Walcheck MT; Nukaya M; Ranheim EA; Matkowskyj KA; Ronnekleiv-Kelly S
Leuk Lymphoma; 2023 Jun; 64(6):1112-1122. PubMed ID: 37081806
[TBL] [Abstract][Full Text] [Related]
38. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of the Euchromatic Histone-Lysine
Urrutia G; de Assuncao TM; Mathison AJ; Salmonson A; Kerketta R; Zeighami A; Stodola TJ; Adsay V; Pehlivanoglu B; Dwinell MB; Zimmermann MT; Iovanna JL; Urrutia R; Lomberk G
Front Cell Dev Biol; 2021; 9():681153. PubMed ID: 34249932
[TBL] [Abstract][Full Text] [Related]
40. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]